This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.
Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is already elevated by obesity, gallstones and alcohol. That said, the labels carry the warning, and the presentation is distinctive enough to act on: severe persistent upper-abdominal pain radiating to the back, usually with vomiting, not relieved by anything.
Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.
The narrow version of the question is what the pooled safety data actually shows for this class, as opposed to what the label warning implies. I would rather have one careful answer than five confident ones.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
JenPlateau said:Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is…
Lipase monitoring while on pancreatitis risk: my doctor checks lipase every 3 months given the theoretical pancreatitis risk. All readings have been normal:
- Baseline: 46 U/L
- Month 3: 41 U/L
- Month 6: 29 U/L
- Month 9: 43 U/L
Normal range is 0-160 U/L. While clinical pancreatitis is rare (<0.5%), I find peace of mind in regular monitoring. Worth asking your doctor about if you're on a GLP-1 long-term.
JenPlateau said:Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is…
Pancreatitis scare with pancreatitis risk: had severe upper abdominal pain radiating to my back at week 8. Went to the ER — they checked lipase and amylase, both normal. Turned out to be a muscle strain.
But I'm glad I went. The risk of pancreatitis, while small (<0.5%), is real. Don't try to tough out severe abdominal pain on a GLP-1 agonist. Get checked.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemAnswering the narrow version, because the broad one does not have a single answer. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.
I would rather be corrected than agreed with, if it comes to it.
labquiet_amy said:Lipase monitoring while on pancreatitis risk: my doctor checks lipase every 3 months given the theoretical pancreatitis risk.
Mine went the same way, slower. I had assumed I was the exception until I read this.